MCE Survey (2008)
An email invitation was sent to the Life Science customer base of MCE
The survey was performed online
229 respondents completed the survey
We segmented the respondents in the following groups:
Industry: traditional pharmaceuticals vs biotech
Level: executive – director – manager – individual contributor
Department: marketing – sales – medical – finance/L&A
Current growth rate: high – medium - low
Expected growth rate: strong – medium - other
Industry ranking (sales): top10 – between 11-20 – lower
We did not get sufficient answers to run subanalyses for generics and OTC companies, and for the
Manufacturing and Discovery Research segments.
20 MCE proprietary
Sales and Drug development will undergo most
of the change by 2010.
(and less so, marketing) are
not seen as areas that will
see major changes.
21 MCE proprietary
Health economics/market access is the key area
where significant investments will be made.
Pharma is putting its bets
on health economics and
R&D. The more traditional
units that have delivered
success of the past will face
a disinvestment strategy.
22 MCE proprietary
Average growth rate in %
Improving relationships is key for S&M
Delta % from average score of
23 MCE proprietary